Delivering a New Generation of Antibody-Drug Conjugates & Antibody Cancer Therapeutics
Time: 3:00 pm
day: Day One P3
Details:
- Advancing clinical stage assets against validated cancer targets and promising preclinical pipeline
- Delivering diversity, selectivity and novel mechanisms of action
- Leveraging unique fully integrated, in-house discovery, development and manufacturing